Clinico-pharmacological studies of sisomicin in ill children.
Sisomicin, at 4.5 mg/kg per day, was prescribed for the therapy of serious bacterial infections of hospitalized infants, children, and adolescents. Eleven children received full treatment courses, with 10 clinical and 9 bacteriological cures. Three patients with underlying disease (two cystic fibrosis and one aplastic anemia) accounted for the failures. Mean half-life was 98.3 min (range, 26.1 to 159.3), and peak serum concentrations 10 min after intravenous infusion were similar (5 to 6 mug/ml) on days 1, 3, and 5 of therapy. Mean urinary concentrations were 54.3 mug/ml; 31 to 47% of the drug was excreted within the 8-h dosage interval. The drug was tolerated well by all patients; however, one patient, receiving the longest duration of therapy (26 days), developed reversible nephrotoxicity.
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D004756:Enterobacteriaceae Infections / Q000188:drug therapy*; D005839:Gentamicins / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007674:Kidney Diseases / Q000139:chemically induced; D007700:Kinetics; D011552:Pseudomonas Infections / Q000188:drug therapy*; D012853:Sisomicin / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*
D005839:Gentamicins; D012853:Sisomicin